Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Advanced pancreatic cancer remains a serious and highly aggressive malignancy associated with substantial morbidity and mortality, particularly among patients with unresectable or metastatic disease. According to the advanced pancreatic cancer epidemiology forecast by Expert Market Research, approximately 50% of patients with pancreatic ductal adenocarcinoma present with metastatic disease. According to Jonah M. Levine et al. (2024), their analysis of 56,757 patients with stage-IV PDAC demonstrated a median overall survival of 4.6 months among patients with liver-only metastases and 8.1 months among those with lung-only metastases.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Advanced Pancreatic Cancer – Number of Cases by Year

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Advanced Pancreatic Cancer Epidemiology Forecast Report Coverage

Expert Market Research's “Advanced Pancreatic Cancer Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Advanced Pancreatic Cancer. It projects the future incidence and prevalence rates of Advanced Pancreatic Cancer cases across various populations. The study covers age, gender, and type as major determinants of the Advanced Pancreatic Cancer population. The report highlights patterns in the prevalence of Advanced Pancreatic Cancer overtime and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Advanced Pancreatic Cancer in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Advanced Pancreatic Cancer Understanding: Disease Overview

Advanced pancreatic cancer is a highly aggressive malignancy, predominantly pancreatic ductal adenocarcinoma (PDAC), characterized by locally unresectable or metastatic disease. Most patients are diagnosed at an advanced stage, limiting the feasibility of curative surgical resection. The disease exhibits marked biological heterogeneity, rapid progression, and frequent metastasis, particularly to the liver, peritoneum, regional lymph nodes, and lungs. Its dense stromal microenvironment, molecular complexity, and intrinsic resistance to systemic therapy contribute to poor long-term outcomes.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

Japan

High-Risk Population

Older adults, particularly individuals aged ≥65 years

Key Diagnostic Method

Contrast-enhanced CT and MRI/MRCP

Major Risk Factor

Cigarette smoking

Major gap in the market

Limited effectiveness of systemic therapies in advanced disease and persistent late diagnosis

Advanced Pancreatic Cancer Epidemiology Perspective

The advanced pancreatic cancer epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Advanced Pancreatic Cancer epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Advanced Pancreatic Cancer and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

According to Jonah M. Levine et al. (2024), approximately 50% of PDAC patients present with metastatic disease. In a study of 56,757 stage-IV PDAC patients, median overall survival ranged from 4.6 months for liver-only metastases to 8.1 months for lung-only metastases, highlighting the substantial burden and poor prognosis of advanced pancreatic cancer.

Gender-Specific Cases of the Disease

According to Esther N. Pijnappel et al. (2022), among 7,470 patients with metastatic pancreatic cancer, 3,884 (52.0%) were men and 3,586 (48.0%) were women. The Netherlands Cancer Registry study covered patients diagnosed with synchronous metastatic pancreatic cancer between 2015 and 2019, indicating a modest male predominance rather than a major sex disparity.

Age-Specific Cases of the Disease

According to Liu et al. (2021), among 10,784 patients with metastatic pancreatic cancer, 7,103 (65.9%) were aged ≥65 years, including 4,415 aged 65–79 years and 2,688 aged ≥80 years. In a separate registry of 422 patients with locally advanced pancreatic cancer, 43% were aged 65–74 years, 38% were <65 years, and 19% were ≥75 years, demonstrating a concentration of advanced disease among older adults.

Ethnicity-Wise Cases of the Disease

According to Al-Hawary et al. (2025), Black patients with metastatic PDAC experienced a longer interval between diagnosis and systemic treatment initiation than White patients, although no significant differences were observed in guideline-concordant first-line treatment or overall survival. Khalaf et al. (2024) reported that Black patients were 19% more likely to present with late-stage disease and 25% less likely to undergo surgical resection; excess mortality disappeared after adjustment for stage and treatment.

Mortality and Survival Analysis of the Disease

According to Levine et al. (2024), approximately 50% of PDAC patients present with metastatic disease, with median overall survival of 4.6 months for liver-only and 8.1 months for lung-only metastases. More recent 2025 real-world evidence reported median overall survival of 7.9 months for liver-only metastatic disease and 4.5 months for multisite metastases, highlighting the substantial mortality burden of advanced pancreatic cancer.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Pancreatic Ductal Adenocarcinoma (PDAC)

PDAC is the predominant histological subtype of pancreatic cancer, accounting for approximately 90% of cases and frequently presenting as unresectable or metastatic disease. The 90% figure refers to pancreatic cancers overall, not specifically advanced disease.

Pancreatic Neuroendocrine Tumors (PanNETs)

PanNETs are uncommon but clinically important in advanced pancreatic malignancy. In a 2023 cohort of 662 patients receiving antitumoral therapy, 85% had stage IV disease, 89.0% had liver metastases, and 93.1% were inoperable, demonstrating the substantial advanced-disease burden among treated patients.

Acinar Cell Carcinoma

Acinar cell carcinoma is rare, representing approximately 0.2–4.3% of pancreatic neoplasms. In a multicenter series of 66 patients, 42% had metastatic disease at diagnosis. Another series of 45 patients reported 11.1% locally advanced and 35.6% metastatic disease, meaning 46.7% had advanced disease at presentation.

Other Pancreatic Malignancies and Histological Variants

Other rare malignancies include pancreatic neuroendocrine carcinoma, adenosquamous carcinoma, undifferentiated carcinoma, colloid carcinoma, signet-ring cell carcinoma, medullary carcinoma, and mixed acinar-neuroendocrine neoplasms. In poorly differentiated pancreatic neuroendocrine carcinoma, 88% had nodal or distant metastases at presentation, with another 7% developing metastases during follow-up.

Advanced Pancreatic Cancer – Number of Cases by Country

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Country-wise Advanced Pancreatic Cancer Epidemiology

The Advanced Pancreatic Cancer epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

Advanced pancreatic cancer represents the majority of pancreatic cancer diagnosed in the United States. Current SEER data indicate that approximately 51% of pancreatic cancers are diagnosed with distant metastatic disease, while a further 28% are diagnosed with regional disease. Distant-stage pancreatic cancer has a 5-year relative survival of only 3.4%, compared with 43.6% for localized disease. Thus, approximately four-fifths of cases present with either regional or distant spread, making advanced disease the principal contributor to the U.S. pancreatic cancer treatment burden.

Germany

Advanced presentation is particularly prominent in Germany. A multicenter analysis of the German Cancer Consortium's clinical communication platform found that pancreatic cancer was most frequently diagnosed at an advanced stage: 45.9% of cases were UICC stage IV, with a further 11.8% at stage III. Consequently, approximately 57.7% of cases were stage III–IV at diagnosis in this registry population. These data demonstrate the substantial German burden of locally advanced and metastatic disease and the corresponding need for systemic and multidisciplinary management.

France

Advanced pancreatic cancer constitutes a major component of the French pancreatic cancer burden. A 2024 French review of metastatic pancreatic adenocarcinoma reported that more than 50% of newly diagnosed pancreatic adenocarcinomas are discovered at an advanced stage. Only approximately 20% of newly diagnosed patients have a tumor considered immediately resectable, while more than two-thirds of patients who undergo initial surgery subsequently relapse, most often with metastatic disease. These findings highlight the predominance of unresectable and metastatic disease in French clinical practice.

Italy

Italy recorded approximately 15,710 new pancreatic cancer cases in 2022, with an ASR of 8.0 per 100,000, while approximately 14,903 deaths were reported. More recent Italian estimates from I Numeri del Cancro in Italia 2024 indicate around 13,585 new diagnoses in 2024, approximately 14,900 deaths in 2022, and only 11–12% five-year net survival, highlighting the disease's poor prognosis and continuing clinical burden.

Spain

Advanced disease is predominant in Spain, where only approximately 10–15% of patients present with a localized, potentially curable tumor, while approximately 50% present with stage IV systemic disease and a further 30–35% present with borderline-resectable or locally advanced disease. Thus, approximately 80–85% of patients present with disease that is not straightforwardly resectable at diagnosis, with metastatic disease alone accounting for approximately half of presentations. These figures emphasize the importance of systemic therapy and multidisciplinary management in the Spanish advanced pancreatic cancer population.

United Kingdom

The United Kingdom has a particularly well-defined late-stage burden. Northern Ireland population-based data for 2017–2021 showed that 49.7% of pancreatic cancer cases were diagnosed at stage IV, rising to 55.5% among cases with a known stage. Only 15.7% of all cases were diagnosed at stage I. More recent national reporting also demonstrates the poor prognosis associated with stage IV disease: in England, among patients diagnosed with exocrine pancreatic cancer during 2021–2022, 7,745 were stage IV, with only 10% surviving one year after diagnosis.

Japan

Japan has one of the clearest contemporary stage-specific datasets. According to Cancer Statistics in Japan 2025, pancreatic cancer cases were distributed as 6.2% stage I, 25.4% stage II, 17.7% stage III, 47.4% stage IV, and 3.3% unknown stage. Therefore, nearly half (47.4%) of pancreatic cancers were already metastatic at diagnosis, while approximately 65.1% were stage III or IV. This demonstrates a substantial advanced-disease burden despite Japan's extensive cancer-screening and specialist-care infrastructure.

India

India has a substantial advanced pancreatic cancer burden despite a comparatively low age-standardized incidence rate. The ICMR consensus document reports that only approximately 10–20% of patients have resectable pancreatic cancer at presentation, indicating that approximately 80–90% present with locally advanced or metastatic/unresectable disease. The same source attributes poor outcomes partly to the fact that pancreatic cancer is frequently asymptomatic until it becomes locally advanced or metastatic. Accordingly, the advanced-disease population represents the clinically dominant segment of pancreatic cancer in India, although a recent nationwide stage-specific registry estimate remains limited.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

Significant gaps remain in the epidemiological characterization and earlier detection of advanced pancreatic cancer, particularly PDAC, as most cases are incurable at presentation. Population-wide screening is not currently recommended, while nonspecific early symptoms and limited biomarkers remain major barriers. Emerging approaches include high-risk surveillance using MRI/MRCP and EUS, multimodal imaging, liquid biopsy, circulating tumor DNA, and AI-assisted detection. In the CAPS5 study, 7 of 9 surveillance-detected PDAC cases (77.8%) were stage I, supporting structured surveillance in high-risk populations. In January 2026, an NIH-supported study identified ANPEP and PIGR as promising blood biomarkers; combined with CA19-9 and THBS2, the four-marker panel achieved 91.9% accuracy at a 5% false-positive rate. Prospective validation remains necessary.

Advanced Pancreatic Cancer: Treatment Overview

The management of advanced pancreatic cancer primarily aims to control tumor progression, prolong survival, alleviate cancer-related symptoms, and preserve quality of life, with systemic therapy forming the cornerstone of treatment for unresectable locally advanced and metastatic pancreatic ductal adenocarcinoma (PDAC). Treatment selection is determined by disease extent, performance status, comorbidities, organ function, patient preferences, and, increasingly, tumor molecular characteristics. According to the 2025 ESMO Clinical Practice Guideline Express Update, NALIRIFOX is a recommended first-line treatment option for patients with metastatic PDAC whose candidates for combination chemotherapy are, alongside established regimens including FOLFIRINOX or modified FOLFIRINOX and gemcitabine plus nab-paclitaxel. The phase III NAPOLI-3 trial demonstrated a median overall survival of 11.1 months with NALIRIFOX compared with 9.2 months with gemcitabine plus nab-paclitaxel, with corresponding improvements in progression-free survival. For patients who are not suitable for intensive combination chemotherapy, gemcitabine-based approaches or fluoropyrimidine-based treatment may be considered according to clinical fitness and treatment objectives.

Key Questions Answered

  • What is the current and projected burden of advanced pancreatic cancer across the 8 major markets?
  • Which countries across the 8 major markets account for the highest advanced pancreatic cancer patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of advanced pancreatic cancer across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of Advanced Pancreatic Cancer across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of Advanced Pancreatic Cancer across the 8 major markets?
  • How do major comorbidities and risk factors influence advanced pancreatic cancer epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of Advanced Pancreatic Cancer across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the advanced pancreatic cancer landscape across the 8 major markets?
  • Which therapeutic areas linked to advanced pancreatic cancer are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the advanced pancreatic cancer epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on advanced pancreatic cancer epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for Advanced Pancreatic Cancer across the 8 major markets?

Scope of the Advanced Pancreatic Cancer Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Advanced Pancreatic Cancer based on several factors.
  • Advanced Pancreatic Cancer Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The Advanced Pancreatic Cancer report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Pancreatic Cancer Drug Pipeline Analysis Report

Pancreatic Neuroendocrine Tumors Epidemiology Forecast

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us